Short Interest in Tempus AI, Inc. (NASDAQ:TEM) Expands By 42.2%

Tempus AI, Inc. (NASDAQ:TEM) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 8,730,000 shares, an increase of 42.2% from the December 15th total of 6,140,000 shares. Based on an average daily volume of 2,340,000 shares, the short-interest ratio is currently 3.7 days. Approximately 17.8% of the company’s stock are sold short.

Tempus AI Stock Performance

NASDAQ:TEM traded down $0.17 during trading hours on Thursday, hitting $34.75. The stock had a trading volume of 2,743,470 shares, compared to its average volume of 4,066,956. The company has a 50 day simple moving average of $47.24 and a two-hundred day simple moving average of $47.17. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI has a one year low of $22.89 and a one year high of $79.49.

Insider Activity

In related news, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew Polovin sold 51,504 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the sale, the executive vice president now owns 246,085 shares in the company, valued at $10,431,543.15. This trade represents a 17.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 865,041 shares of company stock worth $35,917,673 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI in the 3rd quarter valued at about $30,000. Geode Capital Management LLC raised its stake in Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after purchasing an additional 539 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in Tempus AI during the fourth quarter valued at approximately $67,000. Vestor Capital LLC bought a new stake in Tempus AI during the third quarter valued at approximately $153,000. Finally, The Manufacturers Life Insurance Company grew its stake in Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after buying an additional 2,765 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Bank of America lifted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Guggenheim started coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company. Wolfe Research started coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Piper Sandler reissued a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Loop Capital dropped their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.36.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.